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ABSTRACT: Platinum nanoparticles (PtNPs) are antioxidant enzyme-
mimetic nanomaterials with significant potential for the treatment of
complex diseases related to oxidative stress. Among such diseases,
Cerebral Cavernous Malformation (CCM) is a major cerebrovascular
disorder of genetic origin, which affects at least 0.5% of the general
population. Accumulated evidence indicates that loss-of-function
mutations of the three known CCM genes predispose endothelial cells
to oxidative stress-mediated dysfunctions by affecting distinct redox-
sensitive signaling pathways and mechanisms, including pro-oxidant and
antioxidant pathways and autophagy. A multitargeted combinatorial
therapy might thereby represent a promising strategy for the effective
treatment of this disease. Herein, we developed a multifunctional
nanocarrier by combining the radical scavenging activity of PtNPs with
the autophagy-stimulating activity of rapamycin (Rapa). Our results
show that the combinatorial targeting of redox signaling and autophagy dysfunctions is effective in rescuing major molecular and
cellular hallmarks of CCM disease, suggesting its potential for the treatment of this and other oxidative stress-related diseases.
■ INTRODUCTION
Multifactorial diseases, such as cerebrovascular pathologies,
require complex therapeutic approaches based on the
combination of different drugs simultaneously directed at
multiple targets to achieve synergy and efficient therapeutic
response.1−4 Among cerebrovascular diseases, Cerebral Cav-
ernous Malformation (CCM) has emerged as a major health
issue, affecting approximately 24 million people worldwide.5−7
CCM is characterized by vascular lesions consisting of
abnormally dilated and fragile blood capillaries, mainly
occurring in the central nervous system, which expose to a
lifetime risk of seizures, focal neurological deficits, and
hemorrhagic stroke.5−8 Genetic studies have demonstrated
that CCM is caused by loss-of-function mutation in three
CCM genes (KRIT1/CCM1, CCM2, and CCM3)9 implicated
in the maintenance of endothelial cell−cell junction stability
and blood−brain barrier (BBB) integrity.10 Growing evidence
suggests that multiple factors contribute to CCM disease
pathogenesis and its highly variable expressivity.11 Indeed, it
has been shown that loss-of-function of CCM genes affects
major pleiotropic mechanisms involved in cellular redox
homeostasis and defense against oxidative stress, including
the fine-tuned crosstalk between redox signaling and
autophagy.10 In particular, a recent report demonstrates that
KRIT1 loss-of-function causes defective autophagy and
consequent molecular and cellular abnormalities, including
accumulation of the autophagy adapter p62, and abnormal
persistence of dysfunctional mitochondria, leading to a strong
increase in intracellular levels of reactive oxygen species
(ROS).12−14 Importantly, these findings have opened novel
perspectives for the pharmacological treatment of CCM
disease, suggesting that a promising possibility would be the
development of a combinatorial treatment that may simulta-
neously and synergistically target autophagic dysfunction and
antioxidant deficiency.10,14 Consistently, all the potential
therapeutic compounds for CCM disease proposed so far,
including statins,15 N-acetylcysteine,16,17 fasudil,18 tempol,19
vitamin D3,19 sulindac derivatives,20 rapamycin (Rapa),12 and
avenanthramides,21,22 are endowed with either autophagy-
inducing or antioxidant properties or both.10,13,14
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To address the possibility of developing a combinatorial
treatment simultaneously targeting redox signaling and
autophagic dysfunction, we developed a multifunctional
nanocarrier, composed of rapamycin-functionalized platinum
nanoparticles (PtNPs). This multifunctional nanocarrier
combines the intrinsic antioxidant activity of PtNPs23−26 and
the autophagy-stimulating activity of rapamycin.12 PtNPs are
known to act as artificial antioxidant enzymes (nanozymes)
and have proven strong antioxidant activity in cellular models
of CCM disease, being able to restore their physiological ROS
homeostasis.27 Moreover, the nanocarrier may allow the
improvement of the cellular delivery of rapamycin, which is
characterized by poor solubility in aqueous media, limiting its
use as a free drug.28−30 Using established cellular models of
CCM disease, we demonstrated that the combinatorial and
synergistic pro-autophagic and antioxidant activities of the
multifunctional nanocarrier were highly effective in rescuing
major molecular and cellular phenotypes caused by KRIT1
loss-of-function, including defective autophagy, altered ROS
homeostasis, and endothelial-to-mesenchymal transition
(EndMt), suggesting promising therapeutic applications.
■ RESULTS AND DISCUSSION
Preparation and Characterization of Platinum@BSA−
Rapamycin Nanocarrier (Pt5@Rapa NPs). The multifunc-
tional nanocarrier was prepared using biocompatible, endotox-
in-free, and highly catalytic citrate-capped PtNPs of 5 nm,
synthesized as previously reported.27 The radical scavenging
activity of PtNPs was recently proved to restore intracellular
redox homeostasis in a cellular model of CCM disease.27
Although the small size of these NPs may limit their drug-
loading capacity, their superior antioxidant nanozyme proper-
ties (due to their high surface-to-volume ratio) are particularly
promising for the combinatorial treatment of CCM.27 On the
other hand, rapamycin was selected for its proven efficacy in
rescuing defective autophagy in CCM cells.12 Because this
Figure 1. Characterization of Pt5@Rapa NPs. (A) Schematic representation of NP synthesis (features not to scale). (B) Representative
transmission electron microscopy (TEM) image and (C) size distribution analysis of Pt5 NPs. (D) Characterization of Pt5 NPs functionalization
by agarose gel electrophoresis. Left, optical image showing Pt5 NP retention in the agarose gel upon conjugation with fluorescent BSA. Middle,
agarose gel analysis by fluorescent mode acquisition showing BSA conjugation. Right, overlay of optical and fluorescent acquisitions.
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drug has low bioavailability,29 we exploited Bovine Serum
Albumin (BSA) to incorporate rapamycin within the hydro-
phobic pockets of the protein in the attempt to improve its
solubilization and delivery, as well as to protect it from
degradation.31 Figure 1A illustrates our multifunctional
platinum@BSA−rapamycin nanocarrier (Pt5@Rapa NPs). In
particular, citrate-capped PtNPs were coated with two different
thiols, one of them terminating with free carboxylic groups for
the covalent binding of BSA through its amine groups, and the
other one to provide colloidal stability to NPs during the
bioconjugation procedure (see Materials and Methods).
Exposed carboxyls were activated by click chemistry and
covalently coupled to the primary amines of BSA via
carbodiimide reaction. Drug loading was performed by two
approaches: co-incubation of NPs with rapamycin and BSA or
incubation of NPs with rapamycin-loaded BSA. These
procedures gave similar results, provided that a low
concentration of rapamycin is used to preserve the NP
colloidal stability.
TEM analyses showed that Pt5 NPs were highly
monodisperse (Figure 1B), with a size distribution centered
around 5 nm (Figure 1C). The size and the dispersion degree
of Pt5@Rapa NPs were investigated by Dynamic Light
Scattering (DLS). An increase in the average hydrodynamic
Figure 2. (A) Viability of KRIT1-KO MEFs after exposure for 24 and 48 h to 50 μg/mL Pt5 or Pt5@Rapa NPs. Viability of treated cells is
expressed as relative to untreated control cells (CTRL). Data are reported as mean ± standard deviation (SD). (B) Representative confocal
fluorescence images of the internalization of Pt5@Rapa NPs into KRIT1-KO MEFs. Scale bar: 20 μm. Top left: fluorescent Pt5@Rapa NPs (red);
top right: lysosomes stained with LysoTracker Green (green); low left: merged images; low right: magnification of the area in the white box. (C)
Immunoblot analysis of p62 expression in KRIT1-KO MEFs untreated (CTRL) or treated for 15 h with 50 μg/mL Pt5, Pt5@Rapa NPs, or 500 nM
rapamycin. Vinculin was used as a loading control. (D) Quantification of p62 on vinculin in KRIT1-KO MEFs, representative of three independent
Western blot experiments, is reported. (E) ROS levels in KRIT1-KO MEFs untreated (CTRL), or exposed for 15 h to 50 μg/mL of citrate-capped
Pt5, Pt5, Pt5@Rapa NPs, or 500 nM rapamycin was evaluated by dichlorodihydrofluorescein diacetate (DCFH-DA) assay. DCF intensity of
treated KRIT1-KO MEFs is expressed relative to untreated KRIT1-KO MEFs. At least three independent experiments were performed. Data are
expressed as mean ± SD. Differences between treated samples and the control were considered statistically significant for p-values <0.05 (***p <
0.001).
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radius by 30 nm compared to Pt5 NPs was measured
(Supporting Information Table S1). Binding of BSA on Pt5
NPs (Pt5@BSA) was confirmed by agarose gel electrophoresis
(Figure 1D). Pt5@BSA NPs were retained in the agarose gel
due to their higher molecular weight compared to non-
functionalized Pt5 NPs, indicating the successful conjugation
of the protein to the NPs. However, because BSA has
molecular size comparable to our Pt5 NPs, only few BSA
proteins can be conjugated to each NP.32 Actually,
fluorescence analysis showed that each Pt5 NPs contained an
average of 2 conjugated molecules of BSA. Furthermore, as
probed by UV−vis, we estimated that each nanocarrier
transported about two molecules of rapamycin. Although our
nanovector had low drug loading capacity (few rapamycin
molecules per NP), such bioconjugation conditions repre-
sented a good compromise between NP stability and
monodispersion, drug loading, and high antioxidant activity,
all crucial features for our combinatorial therapeutic approach.
Pt5@Rapa NPs for Rapamycin Delivery. To test the
activity of the multifunctional rapamycin nanocarrier, we took
advantage of KRIT1-knockout mouse embryonic fibroblast
(MEF) cells (KRIT1-KO MEFs), an established cellular model
of CCM disease characterized by impaired autophagy and high
levels of intracellular ROS.12,16,17 This cellular model is well
suited for testing combination approaches based on multi-
functional nanocarriers. Several studies demonstrated that
treatments of these cells with distinct compounds, endowed
with antioxidant properties, were capable of recovering
increased intracellular ROS levels and altered redox signal-
ing,16,17,22,27,33 whereas their treatment with rapamycin was
effective in rescuing also defective autophagy.12
We first assessed the toxicological profile of the Pt5@Rapa
nanocarriers on KRIT1-KO MEF cells. Specifically, the
cytocompatibility of Pt5@Rapa NPs was tested at concen-
trations up to 50 μg/mL for 24 and 48 h, by WST-1 assay.
Pt5@Rapa NPs were cytocompatible on MEFs (Figure 2A),
indicating that Pt5 NP conjugation with rapamycin-loaded
BSA does not alter their toxicological profile. Moreover, we
assessed Pt5@Rapa NP cellular uptake and their intracellular
fate by confocal microscopy. Confocal images showed an
efficient internalization of Pt5@Rapa NPs and their
compartmentalization within lysosomes (Figure 2B), confirm-
ing that NP uptake occurs by endocytosis, as previously
demonstrated for nonfunctionalized citrate-capped Pt5 NPs.27
It has been demonstrated that also rapamycin−polymer
conjugates are taken up by the endocytic pathway and
compartmentalized within the lysosomes, where the release
of the drug takes place.28 Accordingly, it is possible to
speculate that, once endocytosed, the attack of peptidases to
Pt5@Rapa NPs within lysosomes may induce the release of
rapamycin from BSA, leading to rapamycin therapeutic action.
The efficacy of Pt5@Rapa NPs as rapamycin delivery system
was tested by quantifying the expression of p62, a typical
autophagic marker that accumulates when autophagy is
inhibited. The total level of p62 was quantified in lysates of
KRIT1-KO MEFs treated with Pt5 or Pt5@Rapa NPs. In
parallel, cells were treated with free rapamycin, at a
concentration known to restore the physiological p62
expression of wild-type cells (Supporting Information Figure
S1).12 Western blot analysis revealed that the accumulation of
p62 significantly decreased upon cell treatment with Pt5@
Rapa NPs (Figure 2C,D), indicating that rapamycin delivered
by the nanocarrier is able to restore cell autophagy with similar
efficiency as the free drug. On the contrary, no change in the
level of p62 expression was detected in cells treated with
nonfunctionalized Pt5 NPs, demonstrating that Pt5 NPs itself
does not interfere with autophagy, unlike some reports with
other metal NPs.34−36 These findings demonstrate that PtNP-
assisted rapamycin delivery is effective to elicit a therapeutic
effect comparable to the free drug, even at a lower drug
concentration. It can be hypothesized that rapamycin
encapsulation within NPs might also have contributed to its
efficacy by protecting it from the degradation and improving its
internalization within the cells. Consistent with our findings,
the use of rapamycin-loaded nanoparticles has been shown to
target defective autophagy in muscular dystrophy and to
enhance both skeletal muscle strength and cardiac contractile
performance, which is not achievable with conventional oral
rapamycin, even in pharmacological doses.37
Pt5@Rapa NPs as Antioxidant Nanocarriers. Citrate-
capped Pt5 NPs were recently found to restore ROS
homeostasis in KRIT1-KO MEFs.27 To assess the ROS
scavenging activity of Pt5@Rapa NPs, KRIT1-KO MEFs were
treated with citrate-capped Pt5, Pt5, Pt5@Rapa NPs, or free
rapamycin and ROS levels were quantified by the dichlor-
odihydrofluorescein diacetate (DCFH-DA) assay. Both Pt5
NPs and the multifunctional nanocarrier exhibited high ROS
scavenging potential, which was comparable to that of
nonfunctionalized citrate-capped Pt5 NPs, even though their
surface is partially covered by thiols and BSA (Figure 2E). This
suggests that the coating does not interfere with the catalytic
reactions (as discussed above, it is likely that BSA molecules
are degraded once in the lysosomal environment). Within the
intracellular environment, Pt5@Rapa NPs exert significant
antioxidant activity, directly reducing the ROS species, unlike
free rapamycin that indirectly regulates the ROS levels by
acting on autophagy pathways that control the clearance of
ROS-generating dysfunctional mitochondria.38 Therefore, the
drug itself has a weak antioxidant activity. Consistently,
additive effect of rapamycin within the nanovector was not
detectable, probably due to its lower concentration on the
nanocarrier compared to that of the free drug. These results
demonstrated that our nanocarrier is also an efficient
modulator of ROS homeostasis in a cellular model of CCM
disease, confirming its potential as multifunctional nanovector
for combination therapy.
Pt5@Rapa NPs as Angiogenesis Modulator. CCM
proteins play a major role in the maintenance of endothelial
cell−cell junction stability and blood−brain barrier (BBB)
integrity through the tight modulation of the interplay between
autophagy and redox homeostasis and signaling.10,14,15,39−43 By
impairing autophagy and dysregulating ROS homeostasis, loss-
of-function of CCM genes, including KRIT1, causes
EndMt,12,20,44 a process whereby endothelial cells lose their
specific markers and cell−cell contacts, weakening their barrier
function.45 In light of this mechanism, we tested the efficacy of
our multifunctional nanocarrier to attenuate or reverse EndMt
and re-establish physiological angiogenesis of KRIT1-depleted
endothelial cells, comparing its effect with that of rapamycin
alone or PtNPs. Once verified the cytocompatibility of Pt5
NPs on wild-type primary Human Umbelical Vein Endothelial
Cells (HUVEC) (Supporting Information Figure S2), the
effect of Pt5 NPs, rapamycin, and Pt5@Rapa NPs was
evaluated on unsilenced and KRIT1-silenced HUVECs
(KRIT1-KO HUVECs) by an in vitro angiogenesis assay
(Figure 3A). The formation of a network of capillary-like
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structures on Matrigel was followed over a period of 6−12 h
after cellular exposure for 15 h to treatments (Figure 3B,C).
Normal angiogenesis was observed in all unsilenced cells,
regardless of the treatments. Conversely, KRIT1 knockdown
completely impaired cell ability to form capillary-like tube
structures. This is in agreement with previous reports showing
that endothelial cells with the loss-of-function of CCM genes
fail to organize into well-formed capillary-like networks.46
Interestingly, KRIT1-KO HUVECs exposed to Pt5 NPs
developed some capillary-like structures, demonstrating that
PtNPs can promote the partial recovery of the endothelial
phenotype of KRIT1-silenced HUVECs. This might be
attributed to the intrinsic property of Pt5 NPs to act as
antioxidant nanozymes, being ROS homeostasis crucial for
normal endothelial cell function and signaling.47 As expected,
also rapamycin treatment was found to be effective in
reactivating some in vitro angiogenesis. Indeed, treatment
with rapamycin was previously demonstrated to reverse EndMt
by increasing the expression of key endothelial cell markers in
KRIT1-KO endothelial cells.12 However, neither the anti-
oxidant treatment with bare nanoparticles nor autophagy
induction with rapamycin alone was sufficient to fully inhibit
EndMt and restore physiological in vitro angiogenesis, further
supporting the requirement of a combined treatment with
antioxidants and autophagy inducers. Remarkably, KRIT1-KO
HUVECs treated with Pt5@Rapa NPs were able to undergo in
vitro angiogenesis almost comparably to unsilenced cells, thus
demonstrating the synergistic effect of the combination of the
two therapeutic activities.
A possible model of the molecular mechanism of Pt5@Rapa
NPs in KRIT1-KO endothelial cells is reported in Figure 4C.
Specifically, the loss-of-function of KRIT1 strongly affects
autophagy, leading to the aberrant accumulation of p62 and
causing an increase in intracellular ROS and the EndMt switch
Figure 3. (A) Immunoblot analysis of KRIT1 silencing in HUVECs transfected with negative control siRNA (unsilenced) or KRIT1 siRNA
(siKRIT1) for 72 h. Vinculin was used as loading control. (B) Quantitative evaluation of tube formation as the number of closed polygons formed
in 8 fields for each experimental condition: unsilenced or KRIT1-silenced HUVECs, left untreated (CTRL) or treated for 15 h with 50 μg/mL of
Pt5 NPs, 500 nM rapamycin, or 50 μg/mL of Pt5@Rapa NPs. All the data are presented as mean ± SD. (C) Representative images of one of three
independent experiments of capillary networks visualized by fluorescent calcein staining. Magnifications are reported in the inserts. Scale bars, 200
μm for full fields and 400 μm for magnified fields.
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(Figure 4A). Cell treatment with rapamycin reactivates
autophagy, thereby decreasing p62 accumulation, partially
reducing the ROS levels and reverting the EndMt switch
(Figure 4B). On the other hand, given the intrinsic ROS-
scavenging activity of the Pt5 NPs core and the pro-autophagic
activity of the conjugated rapamycin, Pt5@Rapa NPs can
directly counteract both increased intracellular ROS levels and
defective autophagy, thus exerting synergistic effects that
efficiently limit the major molecular and cellular dysfunctions
associated with defective autophagy, including ROS over-
production and EndMt. Such a combined action allows
endothelial cells to reacquire their specific phenotype and
function (Figure 4C). Hence, the synergism of Pt5@Rapa NPs
demonstrates the superiority of the combinatorial approach
over the targeting of single molecular pathways, suggesting that
NP-based combinatorial therapies may represent a promising
strategy to treat CCM disease. Furthermore, it is also possible
to speculate that the leaky/abnormal nature of CCM
vasculature would favor NP-based drug delivery in vivo
because NPs may accumulate at the level of the lesions
through the enhanced permeability and retention phenomenon
rather than penetrate through tight endothelial junctions of
normal blood vessels of other tissues, minimizing systemic side
effects and toxicity of the free drug.48 In general, given their
superior performances over classical antioxidant compounds in
terms of long-term stability, prolonged action, and wider
operational conditions,26,27 the multifunctional PtNPs devel-
oped in this work could be adapted to targeted combination
therapy approaches for other oxidative stress-related diseases.
■ CONCLUSIONS
In recent years, nanocarriers have emerged as a promising tool
for the co-delivery of multiple drugs for the combination
therapy of complex diseases. Integrating multiple drugs in a
single nanocarrier has the advantages of beneficially over-
lapping the pharmacological profiles of drugs, reduced toxicity,
and ratiometric drug delivery and offers the possibility to
achieve maximum therapeutic synergy and personalized
treatments.49 Here, we exploited the nanozyme properties
and the versatile surface modification of PtNPs to engineer a
multifunctional drug delivery system with combined antiox-
idant properties and autophagy-stimulating activity to prove
their therapeutic potential in combinatorial treatments. The
CCM cellular model represented a suitable benchmark to
demonstrate the ability of the multifunctional nanovector to
work simultaneously as antioxidant nanozyme and drug
nanocarrier and the superiority of the combinatorial treatment
over single treatments with PtNPs or the free drug alone in
rescuing major phenotypic hallmarks of cellular models of
CCM disease. Our proof-of-concept study also suggests that
PtNPs possess suitable features to be considered for further
investigations as multifunctional nanocarriers in combinatorial
treatments of CCM or other oxidative stress-related complex
diseases. The development of advanced delivery systems,
including those based on pickering emulsions,50 could be
envisaged to attempt possible in vivo translation of the
proposed nanovector.
■ MATERIALS AND METHODS
Synthesis of Pt5 NPs. Immediately after the synthesis of
the citrate-capped Pt5 NPs,27 0.8 mL of a solution 50 mM
sodium 3-mercapto-1-propanesulfonate (Sigma-Aldrich), and 2
mL of a solution 20 mM of 3-mercaptopropionic acid, MPA
(Sigma-Aldrich), were sequentially added to the reaction
mixture. The solution was kept under vigorous stirring for at
least 1 h at 80 °C. Thiol molecules form a self-assembled
monolayer on the citrate-capped Pt5 NPs due to the high
affinity of thiols for noble metals51−56 and the strong Pt−sulfur
interaction.57,58 Afterward, the solution was cooled to room
temperature, washed with Milli-Q water using 50 K Amicon
Ultra centrifugal filters, and stored under 4 °C for future
experiments. Pt5 NPs were then characterized by dynamic light
scattering (DLS) spectroscopy using a Zetasizer Nano ZS
Figure 4. Schematic model of Pt5@Rapa NP mechanism of action in KRIT1-KO cells. (A) KRIT1 loss-of-function impairs autophagy, leading to
the aberrant accumulation of autophagy adapter p62, which, in turn, enhances intracellular ROS and promotes the EndMt switch, the two crucial
events that contribute to CCM progression. (B) Therapeutic reactivation of autophagy with rapamycin in KRIT1-KO cells decreases p62
accumulation, reduces intracellular accumulation of ROS, and inhibits the EndMt switch. (C) PtNPs-based combinatorial treatment exerts
synergistic effects that enhances the efficacy of the therapeutic treatment. Pt5@Rapa NPs in KRIT1-KO cells work as multifunctional nanoplatform
simultaneously acting as ROS-scavenging materials and drug nanocarriers. Pt5@Rapa NPs counterbalance the increase in intracellular ROS levels
through their activity of antioxidant enzymes and deliver rapamycin into the cells to decrease the aberrant accumulation of p62. Together, these
activities restore ROS homeostasis and inhibit EndMt with a higher efficacy than the treatment with rapamycin alone.
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System equipped with a 633 nm He−Ne laser (Malvern
Instruments).
TEM Imaging of Pt5 NPs. The shape and the size of Pt5
NPs were analyzed using the TEM analysis. A dilute solution
of PtNPs dispersed in methanol was deposited on a carbon-
coated grid and left to dry in an oven. The TEM images of NPs
were recorded by using a JEOL JEM 1011 microscope. The
size of PtNPs was determined by ImageJ software, measuring
the diameter of more than 300 NPs.
Preparation of Platinum@BSA−Rapamycin Nano-
carrier (Pt5@Rapa NPs). BSA conjugation with Pt5 NPs
was carried out by a covalent coupling of the carboxylic groups
of the MPA layer with the primary amines of BSA (Sigma-
Aldrich) via carbodiimide chemistry. N-(3-dimethylamino-
propyl)-N-ethylcarbodiimide hydrochloride (EDC) (Sigma-
Aldrich, BioXtra) and N-hydroxysuccinimide (NHS) (Sigma-
Aldrich) were used as cross-linking agents. EDC was used to
mediate the formation of peptide linkages between BSA and
MPA, and NHS for improving the reaction rate and
efficiency.59
Activation of Pt5 NPs was carried out using EDC and NHS
as follows: 15 μL of a solution 30 mg/mL of EDC and 15 μL
of a solution 40 mg/mL of NHS were added to 1 mL of a
solution 300 μg/mL of Pt5 NPs. The reaction mixture was
gently shaken for 5 min at room temperature. The excess of
EDC/NHS was immediately removed from the NP solution by
centrifugation at 15 000 rcf for 30 min. Afterward, the
supernatant was collected in another vial, the pellet was
resuspended in Milli-Q water, and both the solutions were
centrifuged again. This washing procedure was repeated two
more times. The NP solution was then resuspended into 1 mL
of PBS.
Pt5@Rapa nanovector was obtained by adding simulta-
neously 100 μL of a solution of 2 mg/mL of BSA and 20 μL of
a solution 100 μM of rapamycin (CalbioChem) in dimethyl
sulfoxide to 1 mL of EDC/NHS-activated NPs. The solution
was gently shaken and incubated for 2 h at room temperature.
The resultant Pt5@Rapa NPs were washed twice with PBS at
15 000 rcf for 30 min to remove unconjugated BSA and drug
molecules. The hydrodynamic diameter of PtNPs was then
measured by DLS spectroscopy to confirm the successful
bioconjugation. For fluorescence analysis, BSA-conjugated
PtNPs were prepared using Alexa Fluor 647 conjugated BSA
(A34785, Thermofisher).
Gel Electrophoresis of Platinum@BSA NPs. Gel
electrophoresis was carried out for 20 min at 70 V on 0.6%
agarose gel using sodium boric acid buffer pH 8.5. Ten
microliters of two solutions containing 50% glycerol and Pt5 or
Pt5 NPs conjugated to fluorescent BSA was loaded in each
well. Images were taken with Typhoon Trio (GE).
Characterization of Pt5@Rapa NPs. The number of BSA
molecules per PtNP has been quantified by fluorescence
analysis comparing the results with a fluorescent BSA standard
calibration curve. A Infinite 200 Pro Tecan microplate reader
was used for reading the BSA fluorescence intensity, setting the
excitation filter at 647 nm and the emission filter at 680 nm.
The evaluation of the amount of rapamycin per nanovector
has been obtained indirectly by considering the number of
BSA per nanovector and their ability to load rapamycin.
Rapamycin-loading capacity of each BSA protein was
calculated using UV−vis measurements. BSA and rapamycin
were incubated at equimolar ratio for the nanovector synthesis.
The amount of rapamycin that does not get trapped within
BSA is able to pass through the 3 K Amicon Ultra centrifugal
filters and then can be measured by UV−vis.
Cell Culture. Mouse embryonic fibroblasts (MEFs)16 were
cultivated in Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine
serum (Sigma-Aldrich), 100 U/mL penicillin, and 100 mg/mL
streptomycin (Sigma-Aldrich). Human Umbilical Vein Endo-
thelial Cells (HUVECs) were cultivated on 0.1% gelatin
(Sigma-Aldrich) in Medium 200 (Cascade Biologics
Invitrogen cell culture, Cat. no. M-200-500) supplemented
with Low Serum Growth supplement kit (Cascade Biologics
Invitrogen cell culture, Cat. no. S-003-K). Cells were incubated
at 37 °C under a humidified controlled atmosphere with 5%
CO2. The HUVECs were used for experiments between
passages 2 and 6.
WST-1 Assay. In vitro toxicological profile of Pt5 and
Pt5@Rapa NPs on MEFs and HUVECs was evaluated by
WST-1 assay (Sigma-Aldrich) according to the previously
described method.60 Briefly, MEFs (25 000 cells/well) were
plated in a 96-well tissue culture plate in a final volume of 100
μL. After 24 h of adhesion, the culture medium was removed
and replaced with medium containing Pt5 or Pt5@Rapa NPs
at a concentration of 50 μg/mL, up to 24 or 48 h. Afterward,
the cells were washed three times with PBS and incubated for 1
h with medium containing 10% WST. The HUVECs (50 000
cells/well) were plated in a 96-well tissue culture plate in a
final volume of 100 μL. After 24 h of adhesion, the culture
medium was removed and replaced with medium containing a
series of Pt5 NPs dilutions ranging from 10 to 50 μg/mL, and
the cells were cultured for other 24 h. Afterward, the cells were
washed three times with PBS and incubated for 1 h with a
medium containing 10% WST. An Infinite 200 Pro Tecan
microplate reader was used for reading the cell viability results.
DCFH-DA Assay. MEFs (25 000 cells/well) were plated in
96-well microplates (Constar) and exposed to 50 μg/mL of
citrate-capped Pt5, Pt5, Pt5@Rapa NPs, and 500 nM
rapamycin. After 15 h, the cells were washed three times
with PBS with Ca2+ and Mg2+ and incubated at 37 °C for 10
min with 5 μM DCFH-DA (Sigma) in PBS. An Infinite 200
Pro Tecan microplate reader was used for reading the DCF
fluorescence intensity, setting the excitation filter at 480 nm
and the emission filter at 520 nm. The results were normalized
with respect to untreated control cells.
Cell Transfection and siRNA-Mediated Gene Silenc-
ing. For KRIT1 knockdown with small interfering RNA, the
HUVECs were transfected twice with a mix of 4× predesigned
iBONi siRNA against KRIT1 (D-00101-Plus, Ribbox GmbH,
Germany) or an iBONi siRNA negative control (K-00301-
0005-N3, Ribbox GmbH). HiPerFect Transfection Reagent
(Qiagen) was used according to manufacturer’s instructions.
Briefly, on the day of transfection, the HUVECs (2 × 105 cells/
well) were transfected in 6-well dishes with negative control
siRNA or with siRNA against KRIT1 at the final concentration
of 120 nM (30 nM each siRNA). The siRNA transfection
procedure was repeated after 24 h to enhance KRIT1
knockdown efficiency. KRIT1 silencing was monitored by
Western blotting analysis.
Western Blotting. The transfected HUVECs were lysed in
radioimmunoprecipitation assay buffer containing protease and
phosphatase inhibitor cocktails (Sigma-Aldrich) for 20 min on
ice. After centrifugation at 14 000 rpm for 10 min at 4 °C, the
proteins were quantified by Micro BCA Protein Assay kit
(Thermo Fisher Scientific). Total cell lysates containing equal
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amounts of total proteins (20 μg) were separated by 10% mini-
protean TGX precast acrylamide gels (Bio-rad Laboratories)
and electroblotted onto poly(vinylidene difluoride) (PVDF)
membranes (Bio-rad Laboratories).
MEFs (500 000 cells/well) treated for 15 h with 50 μg/mL
of Pt5, Pt5@Rapa NPs, or 500 nM rapamycin were lysed in a
buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 1% sodium dodecyl sulfate,
protease, and phosphatase inhibitor cocktails (Sigma-Aldrich)
for 20 min on ice. After centrifugation at 14 000 rpm for 10
min at 4 °C, the proteins were quantified by Micro BCA
Protein Assay kit (Thermo Fisher Scientific). Total cell lysates
containing equal amounts of total proteins (5 μg) were
separated by 4−20% mini-protean TGX precast acrylamide
gels (Bio-Rad Laboratories) and electroblotted onto PVDF
membranes (Bio-Rad Laboratories). The blots were blocked
with 5% nonfat milk (Sigma-Aldrich) in Tris-buffered saline
(TBS) containing 0.05% Tween 20 for 1 h at room
temperature and incubated overnight at 4 °C with primary
antibodies diluted in TBS 1% BSA. The membranes were then
washed three times with TBS 0.3% Tween 20 and incubated
with appropriate horseradish peroxidase-conjugated secondary
antibodies (1:2500) in TBS 0.3% Tween 20 for 1 h at room
temperature. The proteins were visualized according to
manufacturer’s instruction by an enhanced chemiluminescence
detection system (Bio-Rad) with Typhoon Trio (GE). Protein
band intensity was quantified by using ImageJ software (NIH).
Antibodies. Rabbit polyclonal anti-P62/SQSTM1 anti-
body (P0067, Sigma-Aldrich), rabbit recombinant monoclonal
KRIT1 antibody [EPR16560] (ab196025, Abcam), mouse
monoclonal anti-vinculin antibody (V9264, Sigma-Aldrich),
and goat anti-mouse and anti-rabbit IgG (H + L)-HRP
conjugated secondary antibodies (1706515, 1706515, Bio-
Rad) were used.
Confocal Microscopy. MEFs (10 000 cells/well) cells
were seeded in an 8-well chamber (VWR) and incubated at 37
°C and 5% CO2. After 24 h, the cellular medium was removed
and replaced with 50 μg/mL Pt5@Rapa NPs containing Alexa
Fluor 647 conjugated BSA diluted in fresh FluoroBrite DMEM
medium (Thermo Fisher Scientific). After 30 min, the cells
were imaged with Leica TCS SP8 confocal microscope using a
63× oil immersion objective. Pt5@Rapa NPs were imaged
using a 647 nm excitation wavelength. For lysosomes imaging,
the cells were incubated with 75 nM LysoTracker Green
DND-26 (Molecular probes). After 10 min of incubation, the
medium was removed, cells were washed three times with PBS,
and imaged using a 488 nm excitation wavelength for
LysoTracker Green signal detection.
In Vitro Angiogenesis Assay. Seventy-two hours after
transfection with negative control siRNA or 4× predesigned
KRIT1 siRNA, the HUVECs were incubated with 50 μg/mL
Pt5, Pt5@Rapa NPs, or 500 nM rapamycin. After 15 h, the In
Vitro Angiogenesis Assay (Millipore) was performed following
the manufacturer’s instructions. Briefly, untreated or treated
HUVECs (10 × 103) were plated in each well of a 96-well
plate precoated with 50 μL of ECMatrix (Millipore) in
complete Medium 200. After 4 h of incubation, the samples
were stained with Calcein AM (Thermo Fisher Scientific) for
20 min at 37 °C and the formation of capillary-like structures
was analyzed under an EVOS Cell Imaging microscope
(Thermo Fisher Scientific) at 4× magnification. To evaluate
the degree of angiogenesis progression, the number of closed
polygons formed in eight replicates was counted using ImageJ
software (NIH).
Statistical Analysis. The data are expressed as mean ±
SD. For statistical analysis, GraphPad Prism 5 statistical
analysis software was used (GraphPad Prism version 5.00 for
Windows, GraphPad Prism 5 Software, San Diego, California).
The p-values were calculated using one-way analysis of
variance and compared to the corresponding control by the
Bonferroni post-test. Each experiment was independently
performed at least three times. Differences between treated
samples and controls were considered statistically significant
for p-values < 0.05. (*p < 0.05, **p < 0.01, and ***p < 0.001).
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(30) Yañ́ez, J. A.; Forrest, M. L.; Ohgami, Y.; Kwon, G. S.; Davies,
N. M. Pharmacometrics and delivery of novel nanoformulated PEG-b-
poly(ε-caprolactone) micelles of rapamycin. Cancer Chemother.
Pharmacol. 2008, 61, 133−144.
(31) Karimi, M.; Bahrami, S.; Ravari, S. B.; Zangabad, P. S.;
Mirshekari, H.; Bozorgomid, M.; Shahreza, S.; Sori, M.; Hamblin, M.
R. Albumin nanostructures as advanced drug delivery systems. Expert
Opin. Drug Delivery 2016, 13, 1609−1623.
(32) Bekdemir, A.; Stellacci, F. A centrifugation-based physicochem-
ical characterization method for the interaction between proteins and
nanoparticles. Nat. Commun. 2016, 7, No. 13121.
(33) Antognelli, C.; Trapani, E.; Delle Monache, S.; Perrelli, A.;
Fornelli, C.; Retta, F.; Cassoni, P.; Talesa, V. N.; Retta, S. F. Data in
support of sustained upregulation of adaptive redox homeostasis
mechanisms caused by KRIT1 loss-of-function. Data in Brief 2018,
16, 929−938.
(34) Stern, S. T.; Adiseshaiah, P. P.; Crist, R. M. Autophagy and
lysosomal dysfunction as emerging mechanisms of nanomaterial
toxicity. Part. Fibre Toxicol. 2012, 9, No. 20.
(35) Mao, B.-H.; Tsai, J.-C.; Chen, C.-W.; Yan, S.-J.; Wang, Y.-J.
Mechanisms of silver nanoparticle-induced toxicity and important role
of autophagy. Nanotoxicology 2016, 10, 1021−1040.
(36) Ma, X.; Wu, Y.; Jin, S.; Tian, Y.; Zhang, X.; Zhao, Y.; Yu, L.;
Liang, X.-J. Gold Nanoparticles Induce Autophagosome Accumu-
lation through Size-Dependent Nanoparticle Uptake and Lysosome
Impairment. ACS Nano 2011, 5, 8629−8639.
(37) Bibee, K. P.; Cheng, Y.-J.; Ching, J. K.; Marsh, J. N.; Li, A. J.;
Keeling, R. M.; Connolly, A. M.; Golumbek, P. T.; Myerson, J. W.;
Hu, G.; Chen, J.; Shannon, W. D.; Lanza, G. M.; Weihl, C. C.;
Wickline, S. A. Rapamycin nanoparticles target defective autophagy in
muscular dystrophy to enhance both strength and cardiac function.
FASEB J. 2014, 28, 2047−2061.
(38) Choi, A. M. K.; Ryter, S. W.; Levine, B. Autophagy in Human
Health and Disease. N. Engl. J. Med. 2013, 368, 1845−1846.
ACS Omega Article
DOI: 10.1021/acsomega.8b01653
ACS Omega 2018, 3, 15389−15398
15397
(39) Corr, M.; Lerman, I.; Keubel, J. M.; Ronacher, L.; Misra, R.;
Lund, F.; Sarelius, I. H.; Glading, A. J. Decreased KRIT1 expression
leads to increased vascular permeability and modifies inflammatory
responses in vivo. Arterioscler., Thromb., Vasc. Biol. 2012, 32, 2702−
2710.
(40) Glading, A.; Han, J.; Stockton, R. A.; Ginsberg, M. H. KRIT-1/
CCM1 is a Rap1 effector that regulates endothelial cell−cell
junctions. Int. J. Biochem. Cell Biol. 2007, 179, 247−254.
(41) Maddaluno, L.; Rudini, N.; Cuttano, R.; Bravi, L.; Giampietro,
C.; Corada, M.; Ferrarini, L.; Orsenigo, F.; Papa, E.; Boulday, G.;
Tournier-Lasserve, E.; Chapon, F.; Richichi, C.; Retta, S. F.;
Lampugnani, M. G.; Dejana, E. EndMT contributes to the onset
and progression of cerebral cavernous malformations. Nature 2013,
498, No. 492.
(42) Stockton, R. A.; Shenkar, R.; Awad, I. A.; Ginsberg, M. H.
Cerebral cavernous malformations proteins inhibit Rho kinase to
stabilize vascular integrity. J. Exp. Med. 2010, 207, 881−896.
(43) Zheng, X.; Xu, C.; Di Lorenzo, A.; Kleaveland, B.; Zou, Z.;
Seiler, C.; Chen, M.; Cheng, L.; Xiao, J.; He, J.; Pack, M. A.; Sessa, W.
C.; Kahn, M. L. CCM3 signaling through sterile 20-like kinases plays
an essential role during zebrafish cardiovascular development and
cerebral cavernous malformations. J. Clin. Invest. 2010, 120, 2795−
2804.
(44) Guan, J.; Couldwell, W. T. Evaluating the Role of CCM1 Loss-
of-Function−Induced Endothelial-to-Mesenchymal Transition in
Cavernous Malformation Development. World Neurosurg. 2013, 80,
444−446.
(45) Kovacic, J. C.; Mercader, N.; Torres, M.; Boehm, M.; Fuster, V.
Epithelial- and Endothelial- to Mesenchymal Transition: from
Cardiovascular Development to Disease. Circulation 2012, 125,
1795−1808.
(46) Borikova, A. L.; Dibble, C. F.; Sciaky, N.; Welch, C. M.; Abell,
A. N.; Bencharit, S.; Johnson, G. L. Rho Kinase Inhibition Rescues the
Endothelial Cell Cerebral Cavernous Malformation Phenotype. J. Biol.
Chem. 2010, 285, 11760−11764.
(47) Panieri, E.; Santoro, M. M. ROS signaling and redox biology in
endothelial cells. Cell. Mol. Life Sci. 2015, 72, 3281−3303.
(48) Sutradhar, K. B.; Amin, M. L. Nanotechnology in Cancer Drug
Delivery and Selective Targeting. ISRN Nanotechnol. 2014, 2014, 1−
12.
(49) Gadde, S. Multi-drug delivery nanocarriers for combination
therapy. MedChemComm 2015, 6, 1916−1929.
(50) Wu, J.; Ma, G.-H. Recent Studies of Pickering Emulsions:
Particles Make the Difference. Small 2016, 12, 4633−4648.
(51) Laibinis, P. E.; Whitesides, G. M. omega.-Terminated
alkanethiolate monolayers on surfaces of copper, silver, and gold
have similar wettabilities. J. Am. Chem. Soc. 1992, 114, 1990−1995.
(52) Laibinis, P. E.; Whitesides, G. M. Self-assembled monolayers of
n-alkanethiolates on copper are barrier films that protect the metal
against oxidation by air. J. Am. Chem. Soc. 1992, 114, 9022−9028.
(53) Ron, H.; Cohen, H.; Matlis, S.; Rappaport, M.; Rubinstein, I.
Self-Assembled Monolayers on Oxidized Metals. 4. Superior n-
Alkanethiol Monolayers on Copper. J. Phys. Chem. B 1998, 102,
9861−9869.
(54) Caipa Campos, M. A.; Trilling, A. K.; Yang, M.; Giesbers, M.;
Beekwilder, J.; Paulusse, J. M. J.; Zuilhof, H. Self-Assembled
Functional Organic Monolayers on Oxide-Free Copper. Langmuir
2011, 27, 8126−8133.
(55) Laibinis, P. E.; Whitesides, G. M.; Allara, D. L.; Tao, Y. T.;
Parikh, A. N.; Nuzzo, R. G. Comparison of the structures and wetting
properties of self-assembled monolayers of n-alkanethiols on the
coinage metal surfaces, copper, silver, and gold. J. Am. Chem. Soc.
1991, 113, 7152−7167.
(56) Shaheen, A.; Sturm, J. M.; Ricciardi, R.; Huskens, J.; Lee, C. J.;
Bijkerk, F. Characterization of Self-Assembled Monolayers on a
Ruthenium Surface. Langmuir 2017, 33, 6419−6426.
(57) Petrovykh, D. Y.; Kimura-Suda, H.; Opdahl, A.; Richter, L. J.;
Tarlov, M. J.; Whitman, L. J. Alkanethiols on Platinum: Multi-
component Self-Assembled Monolayers. Langmuir 2006, 22, 2578−
2587.
(58) Li, Z.; Chang, S.-C.; Williams, R. S. Self-Assembly of
Alkanethiol Molecules onto Platinum and Platinum Oxide Surfaces.
Langmuir 2003, 19, 6744−6749.
(59) Fischer, M. J. Amine Coupling Through EDC/NHS: A
Practical Approach. In Surface Plasmon Resonance; Mol, N., Fischer,
M., Eds.; Humana Press, 2010; Vol. 627, pp 55−73.
(60) Brunetti, V.; Chibli, H.; Fiammengo, R.; Galeone, A.; Malvindi,
M. A.; Vecchio, G.; Cingolani, R.; Nadeau, J. L.; Pompa, P. P. InP/
ZnS as a safer alternative to CdSe/ZnS core/shell quantum dots: in
vitro and in vivo toxicity assessment. Nanoscale 2013, 5, 307−317.
ACS Omega Article
DOI: 10.1021/acsomega.8b01653
ACS Omega 2018, 3, 15389−15398
15398
